Related Experiment Video

Updated: Jun 21, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

New therapeutic targets in the treatment of prostate cancer

Vivek Vijjan1, Deepak Dubey

  • 1Department of Urology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Rae Bareli Road, Lucknow - 226 014, India.

Indian Journal of Urology : IJU : Journal of the Urological Society of India
|August 14, 2009
PubMed

Insights

Androgen deprivation therapy is standard for advanced prostate cancer but eventually fails. This review explores novel therapies targeting molecular pathways for hormone-refractory prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Urology

Background:

  • Androgen deprivation therapy (ADT) is the primary treatment for advanced prostate cancer.
  • Hormonal manipulations used in ADT eventually become ineffective, leading to hormone-refractory disease.
  • Advances in molecular oncology reveal insights into prostate cancer cell death mechanisms.

Purpose of the Study:

  • To review current literature on emerging therapeutic agents for advanced prostate cancer.
  • To explore novel treatment strategies for hormone-refractory prostate cancer.
  • To highlight the potential of new insights into cellular mechanisms for developing better therapies.

Main Methods:

  • Literature review of current research on prostate cancer therapies.
  • Focus on novel agents including tumor vaccines, angiogenesis inhibitors, and gene-targeted therapies.
  • Examination of agents acting on molecular pathways, cell death regulation, and hormone receptors.

Main Results:

  • ADT is effective but resistance develops, necessitating new treatments.
  • Various novel agents are under development, targeting different cellular mechanisms.
  • Understanding of prostate cancer cell death pathways is improving therapeutic strategies.

Conclusions:

  • New therapeutic agents show promise for treating hormone-refractory prostate cancer.
  • Targeting molecular pathways and cellular mechanisms can lead to more effective therapies.
  • Further research into novel agents and molecular oncology is crucial for advancing prostate cancer treatment.
Keywords:
Anti-apoptotic agentsharmone refractory prostate cancermolecular oncologyprostate cancer

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...